Latest filings (excl ownership)
10-K/A
2023 FY
Annual report (amended)
29 Apr 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
Precigen Reports Full Year 2023 Financial Results and Business Updates
19 Mar 24
8-K
Departure of Directors or Certain Officers
8 Feb 24
EFFECT
Notice of effectiveness
18 Jan 24
CORRESP
Correspondence with SEC
12 Jan 24
8-K
Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference
8 Jan 24
UPLOAD
Letter from SEC
4 Jan 24
S-3
Shelf registration
29 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs
9 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Results of Operations and Financial Condition
9 Aug 23
S-8
Registration of securities for employees
6 Jul 23
8-K
Departure of Directors or Certain Officers
9 Jun 23
10-Q
2023 Q1
Quarterly report
10 May 23
8-K
Precigen Reports First Quarter 2023 Financial Results and Business Updates
10 May 23
ARS
2022 FY
Annual report to shareholders
25 Apr 23
DEFA14A
Additional proxy soliciting materials
25 Apr 23
DEF 14A
Definitive proxy
25 Apr 23
8-K
Entry into a Material Definitive Agreement
4 Apr 23
8-K
Regulation FD Disclosure
13 Mar 23
10-K
2022 FY
Annual report
6 Mar 23
8-K
Precigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
6 Mar 23
8-K
Entry into a Material Definitive Agreement
27 Jan 23
424B5
Prospectus supplement for primary offering
25 Jan 23
424B5
Prospectus supplement for primary offering
24 Jan 23
8-K
Results of Operations and Financial Condition
24 Jan 23
8-K
Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference
11 Jan 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
8-K
Precigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs
9 Nov 22
8-K
Precigen Names Rutul R. Shah Chief Operating Officer
21 Sep 22
8-K/A
Financial Statements and Exhibits
24 Aug 22
8-K
Precigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics
22 Aug 22
424B5
Prospectus supplement for primary offering
9 Aug 22
8-K
Entry into a Material Definitive Agreement
9 Aug 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
8-K
Precigen Reports Second Quarter and First Half 2022 Financial Results
8 Aug 22
8-K
Other Events
13 Jul 22
8-K
Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics
5 Jul 22
Latest ownership filings
4
Jeffrey Thomas Perez
3 May 24
SC 13D/A
KIRK RANDAL J
3 May 24
4
RANDAL J KIRK
3 May 24
4
Harry Jr. Thomasian
9 Apr 24
4
Jeffrey Thomas Perez
9 Apr 24
4
Helen Sabzevari
9 Apr 24
4
Rutul R Shah
9 Apr 24
4
Donald P. Lehr
9 Apr 24
4
RANDAL J KIRK
18 Mar 24
4
Fred Hassan
18 Mar 24
4
Vinita D Gupta
18 Mar 24
4
CESAR L ALVAREZ
18 Mar 24
4
JEFFREY B KINDLER
18 Mar 24
4
DEAN J MITCHELL
18 Mar 24
4
James S Turley
18 Mar 24
4
Steven Frank
18 Mar 24
4
Steven Frank
12 Mar 24
4
DEAN J MITCHELL
12 Mar 24
4
Fred Hassan
12 Mar 24
4
Vinita D Gupta
12 Mar 24
4
CESAR L ALVAREZ
12 Mar 24
4
JEFFREY B KINDLER
12 Mar 24
4
James S Turley
12 Mar 24
4
RANDAL J KIRK
12 Mar 24
SC 13G/A
Patient Capital Management, LLC
27 Feb 24
SC 13G
Patient Capital Management, LLC
14 Feb 24
SC 13G/A
Ares Trading S.A.
14 Feb 24
4
RANDAL J KIRK
29 Dec 23
4
JEFFREY B KINDLER
29 Dec 23
4
DEAN J MITCHELL
25 Sep 23
4
Helen Sabzevari
25 Aug 23
4
Donald P. Lehr
25 Aug 23
4
Rutul R Shah
25 Aug 23
4
Jeffrey Thomas Perez
25 Aug 23
4
Harry Jr. Thomasian
25 Aug 23
4
Jeffrey Thomas Perez
18 Aug 23
4
Harry Jr. Thomasian
18 Aug 23
4
Donald P. Lehr
18 Aug 23
4
Rutul R Shah
18 Aug 23
4
Helen Sabzevari
18 Aug 23